NewAmsterdam Pharma (NAMSW) EBT (2023 - 2025)
Historic EBT for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to -$72.0 million.
- NewAmsterdam Pharma's EBT fell 33251.44% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 1115.34%. This contributed to the annual value of -$241.6 million for FY2024, which is 3656.61% down from last year.
- As of Q3 2025, NewAmsterdam Pharma's EBT stood at -$72.0 million, which was down 33251.44% from -$17.4 million recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year EBT high stood at -$16.6 million for Q3 2024, and its period low was -$93.8 million during Q1 2024.
- Its 3-year average for EBT is -$49.8 million, with a median of -$42.0 million in 2023.
- As far as peak fluctuations go, NewAmsterdam Pharma's EBT soared by 6467.87% in 2024, and later crashed by 33251.44% in 2025.
- Over the past 3 years, NewAmsterdam Pharma's EBT (Quarter) stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then increased by 21.88% to -$72.0 million in 2025.
- Its EBT stands at -$72.0 million for Q3 2025, versus -$17.4 million for Q2 2025 and -$39.5 million for Q1 2025.